RxDoctor Payments Data

Gary Trey, MD

Gastroenterology · Brookline, MANPI 1508853417

Payments from drug & device makers

$4,753in general payments, 2019–2025

Across 219 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$461
  • Johnson & Johnson$263
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$216
  • Gilead$215
  • Biohaven Pharmaceutical Holding Company Ltd.$150
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,70299%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,753 in reported general payments places this provider in the 65th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$66,490
Medicare patients
237
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$321,417
OzempicSemaglutide73$70,107
EliquisApixaban47$47,918
TrulicityDulaglutide48$47,696
MounjaroTirzepatide36$43,568
LinzessLinaclotide42$41,506
JardianceEmpagliflozin34$40,339
CreonLipase/Protease/Amylase18$36,684
Tresiba Flextouch U-100Insulin Degludec11$10,695
ImitrexSumatriptan Succinate12$8,172
Mesalamine19$7,608
Ursodiol29$5,596
Lubiprostone28$4,714
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$4,162
Rosuvastatin Calcium156$3,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$263$321,41712 claims
Lilly USA, LLCTrulicity, Mounjaro$147$91,26484 claims
AbbVieLinzess, Creon, Armour Thyroid$1,904$78,95076 claims
Novo NordiskOzempic$32$70,10773 claims
PfizerEliquis$461$47,91847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Brookline

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →